Loading...
Loading...
BIOC| Name | Value |
|---|---|
| Revenues | 19.9M |
| Cost of Revenue | 10.3M |
| Gross Profit | 9.6M |
| Operating Expense | 12.3M |
| Operating I/L | -2.7M |
| Other Income/Expense | -0.1M |
| Interest Income | 0.0M |
| Pretax | -2.8M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -2.8M |
Biocept, Inc. is a molecular oncology diagnostics company specializing in proprietary assays for circulating tumor cells and cell-free tumor DNA and RNA. These assays provide crucial information to healthcare providers for identifying oncogenic alterations in cancer patients, enabling targeted therapy selection at diagnosis, progression, and monitoring for resistance mechanisms. The company offers assays for various solid tumor indications, including breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. Additionally, Biocept provides testing services to medical professionals, clinical trial and research services to pharmaceutical companies, and RT-PCR testing services for COVID-19.
